Specialty Pharmacy

National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice is the first nationwide precision oncology trail for patients with cancers that have not responded to standard treatments.

Officials with the FDA approved ruxolitinib (Jakafi, Incyte), the first treatment for patients 12 years and older with steroid-refractory acute graft-versus-host disease.

The drug, onasemnogene abeparvovec-xioi (Zolgensma, AveXis), is an adeno-associated virus vector-based gene therapy that targets the cause of SMA, a leading genetic cause of infant mortality.

Top news of the week from Specialty Pharmacy Times.

Researchers seek to investigate how to broaden the potential of cediranib with and olaparib to treat multiple cancer types.

Top news of the day from across the health care landscape.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Among the most prevalent symptoms of chimeric antigen receptor T-cell therapy is encephalopathy.

Study suggests a possible co-treatment strategy to overcome resistance to Venetoclax in the treatment of chronic lymphocyte leukemia and acute myeloid leukemia.

Using real-time data helped providers identify racial disparities in cancer treatment and narrow the gap in treatment completion rates between white and black patients.

Study examines cutting off glutamine and fatty acids, two well-known cancer food sources that tumors use to grow and survive.

Top news of the day from across the health care landscape.

Research may lead to potential new targets for preventing cancer in humans.

Glenmark Pharmaceuticals and Alembic Pharmaceuticals have both received FDA approval for generic Solifenacin Succinate tablets.

Statins can benefit patients with secondary progressive multiple sclerosis for reasons unrelated to their cholesterol-lowering effects.

Top news of the day from across the health care landscape.

Midazolam (Nayzilam) is indicated for seizures that are distinct from a patient's usual seizure pattern, in individuals age 12 years and older with epilepsy.

Study suggests future interventions targeting improvements in cancer screenings may need to focus on the time of day when a patient visits a doctor.

The study focused on the comparative risk of infection across 7 systemic biologics.

Top news of the day from across the health care landscape.

Matthew Malachowski, PharmD, BCPS, supervisor of specialty pharmacy services at UAB Health System, discusses how to optimize collaboration among the health care team to prepare for changes that occur throughout the course of a patient's care.

Officials with the FDA have approved extending the indication of Takeda Pharmaceuticals’ teduglutide (Gattex) for injection to pediatric patients age 1 year and older with Short Bowel Syndrome who need additional nutrition or fluids from intravenous feeding.

The convenience of home infusion for these products is very enticing for patients who require them and positioning home infusion pharmacies as partners with prescribers and patients is critical to help support this influx of new therapies.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Dalteparin sodium is the first anticoagulant indicated for pediatric patients approved by the agency.

An analysis showed short-term health plans can expose enrollees to significant out-of-pocket costs for serious illnesses, such as cancer.